Tipsheet
What matters at India’s listed companies
Order Wins · Engineering - Construction · Micro cap

Fabtech lands ₹31 cr Botswana vaccine plant order

Turnkey order from Botswana Vaccine Institute for HVAC and clean rooms; represents ~7% of FY26 revenue and is a genuine new disclosure.


Mkt cap₹648 cr
P/E26.73×
ROE26.83%
Debt / eq.0.32
Div yld0.41%
₹31.23 cr Turnkey order from Botswana Vaccine Institute

What's new

  • Won turnkey order worth ₹31.23 cr from Botswana Vaccine Institute.
  • Contract covers design, supply, installation, testing, commissioning over 14 months.
  • Order represents ~7% of FY26 revenue, ~5% of market cap; new disclosure.

Why this matters

This order materially boosts revenue visibility for the micro-cap and extends its geographical footprint into Africa. At ~7% of FY26 revenue, the order is significant relative to company scale and is a genuine surprise as there was no prior indication. It validates Fabtech's capability in international cleanroom projects.

What we're watching

  • Execution timeline of 14 months and any further orders from Botswana.
  • Impact on order book and revenue guidance for FY27.
  • Potential for more African contracts given this reference.

The full read

Fabtech Technologies has secured a ₹31.23 crore turnkey order from Botswana Vaccine Institute — its first African contract of this scale. It's a clean win. The deal runs 14 months, covering design through commissioning. At 7% of FY26 revenue and 5% of market cap, this is material for the micro-cap. More important: no prior filings hinted at this, making it a genuine surprise. The order validates Fabtech's international competitiveness and diversifies its geography beyond the Middle East and India. Execution is the next test; the open question is whether this opens the door for more African business.

Questions answered

What is the order value and who is the client?
The order is worth ₹31.23 crore from Botswana Vaccine Institute Limited for HVAC and Clean Room systems.
How significant is this order relative to Fabtech's size?
It represents about 7% of FY26 consolidated revenue of ₹431.33 crore and 4.78% of its market cap.
Is this order a new disclosure or was it anticipated?
It is a genuine new disclosure with no prior indication in recent filings, likely to surprise the market positively.
What is the execution timeline?
The contract has a 14-month execution timeline from design to commissioning.
What does this mean for Fabtech's geographical presence?
It expands Fabtech's footprint in Africa, complementing its existing Middle East and domestic operations.
Mentioned: Botswana Vaccine Institute · ₹31.23 cr · Fabtech Technologies
Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.